Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 4204

Next Previous
Drug Profile

IRX 4204

Alternative Names: AGN-194204; ALRT-4204; IRX-4204; NRX-194204; NRX-4204; VTP-194204

Latest Information Update: 18 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Icahn School of Medicine at Mount Sinai; Io Therapeutics
  • Class Anti-inflammatories; Antidementias; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Prostate cancer
  • Phase I HER2 positive breast cancer; Parkinson's disease
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Arthritis; Multiple myeloma; Neurodegenerative disorders
  • Discontinued Multiple sclerosis

Most Recent Events

  • 11 Dec 2025 Pharmacodynamics data from a preclinical trial in Breast cancer released by Io Therapeutics
  • 06 Dec 2025 Preclinical trials in Multiple myeloma in USA (PO), prior to December 2025
  • 06 Dec 2025 Pharmacodynamics data from a preclinical trial in Multiple myeloma released by Io Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top